Sustained Elevation of Pulsatile Growth Hormone (GH) Secretion and Insulin-Like Growth Factor I (IGF-I), IGF-Binding Protein-3 (IGFBP-3), and IGFBP-5 Concentrations during 30-Day Continuous Subcutaneous Infusion of GH-Releasing Peptide-2 in Older Men and Women

Journal of Clinical Endocrinology and Metabolism

Volumn 89, Issue 5, 2004, Pages 2290-2300

  Bowers, Cyril Y ^a   Granda, Ramona ^a   Mohan, Subburaman ^b   Kuipers, Jonathan ^c   Baylink, David ^b   Veldhuis, Johannes D ^c  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b LOMA LINDA UNIVERSITY   (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; PLACEBO; PRALMORELIN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN BINDING PROTEIN 5; SOMATOMEDIN C;

AGED; AGING; ARTICLE; CONCENTRATION RESPONSE; DOSE TIME EFFECT RELATION; DRUG SAFETY; ELDERLY CARE; FEMALE; GROWTH HORMONE RELEASE; HORMONAL REGULATION; HORMONE DETERMINATION; HUMAN; HUMAN EXPERIMENT; HYPOTHESIS; MALE; NORMAL HUMAN; PEPTIDE ANALYSIS; PRIORITY JOURNAL; PROTEIN BINDING; PULSATILE HORMONE RELEASE; SOMATIC CELL;

AGED; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMAN GROWTH HORMONE; HUMANS; INFUSION PUMPS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 5; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; OLIGOPEPTIDES; OSMOLAR CONCENTRATION; PULSATILE FLOW; REFERENCE VALUES;

EID: 2442597828     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2003-031799     Document Type: Article

References (99)

1. Bowers CY, Chang J, Momany F, Folkers K 1977 Effect of the enkephalins and enkephalin analogs on release of pituitary hormones in vitro. In: MacIntyre I, Szelke M, eds. Molecular endocrinology. Amsterdam: Elsevier; 287-292
2. Bowers CY, Momany FA, Reynolds A, Hong A 1984 On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology 114:1537-1545
3. Howard AD, Feighner SD, Cully DF, Arena JP, Liberator PA, Rosenblum CI, Hamelin M, Hreniuk DL, Palyha OC, Anderson J, Paress PS, Diaz C, Chou M, Liu KK, McKee KK, Pong SS, Chaung LY, Elbrecht A, Dashkevicz M, Heavens R, Rigby M, Sirinathsinghji DJS, Dean DC, Melillo DG, van der Ploeg LH 1996 A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 273:974-977
4. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K 1999 Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402:656-660
5. Bowers CY 1998 Synergistic release of growth hormone by GHRP and GHRH: scope and implication. In: Bercu BB, Walker RF, eds. Growth hormone secretagogues in clinical practice. New York: Marcel Dekker; 1-25
6. Roelfsema F, Biermasz NR, Veldman RG, Veldhuis JD, Frolich M, Stokvis-Brantsma WH, Wit J-M 2000 Growth hormone (GH) secretion in patients with an inactivating defect of the GH-releasing hormone (GHRH) receptor is pulsatile: evidence for a role for non-GHRH inputs into the generation of GH pulses. J Clin Endocrinol Metab 86:2459-2464
7. Pandya N, DeMott-Friberg R, Bowers CY, Barkan AL, Jaffe CA 1998 Growth hormone (GH)-releasing peptide-6 requires endogenous hypothalamic GH-releasing hormone for maximal GH stimulation. J Clin Endocrinol Metab 83:1186-1189
8. Popovic V, Damjanovic S, Micic D, Djurovic M, Dieguez C, Casanueva FF 1995 Blocked growth hormone-releasing peptide (GHRP-6)-induced GH secretion and absence of the synergistic action of GHRP-6 plus GH-releasing hormone in patients with hypothalamopituitary disconnection: evidence that GHRP-6 main action is exerted at the hypothalamic level. J Clin Endocrinol Metab 80:942-947
9. Arvat E, Maccario M, Di Vito L, Broglio F, Benso A, Gottero C, Papotti M, Muccioli G, Dieguez C, Casanueva FF, Deghenghi R, Camanni F, Ghigo E 2001 Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone. J Clin Endocrinol Metab 86:1169-1174
10. Hataya Y, Akamizu T, Takaya K, Kanamoto N, Ariyasu H, Saijo M, Moriyama K, Shimatsu A, Kojima M, Kangawa K, Nakao K 2001 A low dose of ghrelin stimulates growth hormone (GH) release synergistically with GH-releasing hormone in humans. J Clin Endocrinol Metab 86:4552
11. Inui A 2001 Ghrelin: an orexigenic and somatotrophic signal from the stomach. Nat Rev Neurosci 2:551-560
12. Cordido F, Penalva A, Dieguez C, Casanueva FF 1993 Massive growth (GH) discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6: evidence for a marked somatotroph secretory capability in obesity. J Clin Endocrinol Metab 76:819-823
13. Tannenbaum GS, Epelbaum J, Bowers CY 2003 Interrelationship between the novel peptide ghrelin, somatostatin and growth hormone-releasing hormone in regulation of pulsatile growth hormone secretion. Endocrinology 144:967-974
14. Guillaume V, Magnan E, Cataldi M, Dutour A, Sauze N, Renard M, Razafindraibe H, Conte-Devolx B, Deghenghi R, Lenaerts V 1994 Growth hormone (GH)-releasing hormone secretion is stimulated by a new GH-releasing hexapeptide in sheep. Endocrinology 135:1073-1076
15. Fletcher TP, Thomas GB, Clarke IJ 1996 Growth hormone-releasing and somatostatin concentrations in the hypophysial portal blood of conscious sheep during the infusion of growth hormone-releasing peptide-6. Dom Anim Endocrinol 13:251-258
16. 2 in the rat. Endocrinology 117:1441-1447
17. Di Vito L, Broglio F, Benso A, Gottero C, Prodam F, Papotti M, Muccioli G, Dieguez C, Casanueva FF, Deghenghi R, Ghigo E, Arvat E 2002 The GH-releasing effect of ghrelin, a natural GH secretagogue, is only blunted by the infusion of exogenous somatostatin in humans. Clin Endocrinol (Oxf) 56:643-648
18. Dickson SL, Viltart O, Bailey AR, Leng G 1997 Attenuation of the growth hormone secretagogue induction of Fos protein in the rat arcuate nucleus by central somatostatin action. Neuroendocrinology 66:188-194
19. Shuto Y, Shibasaki T, Otagiri A, Kuriyama H, Ohata H, Tamura H, Kamegai J, Sugihara H, Oikawa S, Wakabayashi I 2002 Hypothalamic growth hormone secretagogue receptor regulates growth hormone secretion, feeding, and adiposity. J Clin Invest 109:1429-1436
20. Giustina A, Veldhuis JD 1998 Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev 19:717-797
21. Mueller EE, Locatelli V, Cocchi D 1999 Neuroendocrine control of growth hormone secretion. Physiol Rev 79:511-607
22. Frohman LA 1996 New insights into the regulation of somatotrope function using genetic and transgenic models. Metabolism 45:1-3
23. Huhn WC, Hartman ML, Pezzoli SS, Thorner MO 1993 Twenty-four-hour growth hormone (GH)-releasing peptide (GHRP) infusion enhances pulsatile GH secretion and specifically attenuates the response to a subsequent GHRP bolus. J Clin Endocrinol Metab 76:1202-1208
24. Rahim A, O'Neill PA, Shalet SM 1998 Growth hormone status during long-term hexarelin therapy. J Clin Endocrinol Metab 83:1644-1649
25. Van den Berghe G, de Zegher F, Veldhuis JD, Wouters P, Verbruggen W, Awouters M, Schetz M, Verwaest C, Lauwers P, Bouillon R, Bowers CY 1997 The somatotropic axis in critical illness: effects of continuous GHRH and GHRP-2 infusion. J Clin Endocrinol Metab 82:590-599
26. Malmlof K, Bauer MK, Johansen PB, Ankersen M, Veldhuis JD 2002 Daily low-dose GH secretagogue administration stimulates pulsatile GH secretion and elevates plasma IGF-I levels in pigs. Endocrine 16:195-199
27. Shah N, Evans WS, Bowers CY, Veldhuis JD 1999 Tripartite neuroendocrine activation of the human growth-hormone (GH) axis in women by continuous 24-hour GH-releasing peptide (GHRP-2) infusion: pulsatile, entropic, and nyc-tohemeral mechanisms. J Clin Endocrinol Metab 84:2140-2150
28. Shah N, Evans WS, Bowers CY, Veldhuis JD 2000 Oral estradiol administration modulates continuous intravenous growth hormone (GH)-releasing peptide-2 driven GH secretion in postmenopausal women. J Clin Endocrinol Metab 85:2649-2659
29. Veldhuis JD, Evans WS, Bowers CY 2002 Impact of estradiol supplementation on dual peptidyl drive of growth-hormone secretion in postmenopausal women. J Clin Endocrinol Metab 87:859-866
30. Bowers CY, Granda-Ayala R 1999 Stimulated release of GH in normal younger and older men and women. In: Veldhuis JD, Giustina A, eds. Sex-steroid interactions with growth hormone. New York: Springer; 277-289
31. Jaffe CA, Ho PJ, DeMott-Friberg R, Bowers CY, Barkan AL 1993 Effects of a prolonged growth hormone (GH)-releasing peptide infusion on pulsatile GH secretion in normal men. J Clin Endocrinol Metab 77:1641-1647
32. Horvath TL, Diano S, Sotonyi P, Heiman M, Tschop M 2001 Minireview: ghrelin and the regulation of energy balance: a hypothalamic perspective. Endocrinology 142:4163-4169
33. Bowers CY 2002 New insight into the control of growth hormone secretion. In: Kleinberg DL, Clemmons DR, eds. Central and peripheral mechanisms in pituitary disease. Bristal: BioScientifica; 163-176
34. Iranmanesh A, South S, Liem AY, Clemmons D, Thomer MO, Weltman A, Veldhuis JD 1998 Unequal impact of age, percentage body fat, and serum testosterone concentrations on the somatotrophic, IGF-I, and IGF-binding protein responses to a three-day intravenous growth hormone-releasing hormone pulsatile infusion in men. Eur J Endocrinol 139:59-71
35. Mueller EE, Cella SG, Parenti M, Deghenghi R, Locatelli V, De GC, V, Torsello A, Cocchi D 1995 Somatotropic dysregulation in old mammals. Horm Res 43:39-45
36. Ghigo E, Arvat E, Gianotti L, Ramunni J, Di Vito L, Maccagno B, Grottoli S, Camanni F 1996 Human aging and the GH-IGF-I axis. J Pediatr Endocrinol Metab 9:271-278
37. Iranmanesh A, Grisso B, Veldhuis JD 1994 Low basal and persistent pulsatile growth hormone secretion are revealed in normal and hyposomatotropic men studied with a new ultrasensitive chemiluminescence assay. J Clin Endocrinol Metab 78:526-535
38. Veldhuis JD, Liem AY, South S, Weltman A, Weltman J, Clemmons DA, Abbott R, Mulligan T, Johnson ML, Pincus SM, Straume M, Iranmanesh A 1995 Differential impact of age, sex-steroid hormones, and obesity on basal versus pulsatile growth hormone secretion in men as assessed in an ultrasensitive chemiluminescence assay. J Clin Endocrinol Metab 80:3209-3222
39. Gentili A, Mulligan T, Godschalk M, Clore J, Patrie J, Iranmanesh A, Veldhuis JD 2002 Unequal impact of short-term testosterone repletion on the somatotropic axis of young and older men. J Clin Endocrinol Metab 87:825-834
40. Bergendahl M, Iranmanesh A, Evans WS, Veldhuis JD 2000 Short-term fasting selectively suppresses leptin pulse mass and 24-hour rhythmic leptin release in healthy mid-luteal phase women without disturbing leptin pulse frequency or its entropy control (pattern orderliness). J Clin Endocrinol Metab 85:207-213
41. Mohan S, Bautista CM, Herring SJ, Linkhart TA, Baylink DJ 1990 Development of valid methods to measure insulin-like growth factors-I and -II in bone cell-conditioned medium. Endocrinology 126:2534-2542
42. Honda Y, Landale EC, Strong DD, Baylink DJ, Mohan S 1996 Recombinant synthesis of insulin-like growth factor-binding protein-4 (IGFBP-4): development, validation, and application of a radioimmunoassay for IGFBP-4 in human serum and other biological fluids. J Clin Endocrinol Metab 81:1389-1396
43. Mohan. S, Libanati C, Dony C, Lang K, Srinivasan N, Baylink DJ 1995 Development, validation, and application of a radioimmunoassay for insulin-like growth factor binding protein-5 in human serum and other biological fluids. J Clin Endocrinol Metab 80:2638-2645
44. Veldhuis JD, Carlson ML, Johnson ML 1987 The pituitary gland secretes in bursts: appraising the nature of glandular secretory impulses by simultaneous multiple-parameter deconvolution of plasma hormone concentrations. Proc Natl Acad Sci USA 84:7686-7690
45. Veldhuis JD, Johnson ML 1995 Specific methodological approaches to selected contemporary issues in deconvolution analysis of pulsatile neuroendocrine data. Methods Neurosci 28:25-92
46. Anderson SM, Shah N, Evans WS, Patrie JT, Bowers CY, Veldhuis JD 2001 Short-term estradiol supplementation augments growth hormone (GH) secretory responsiveness to dose-varying GH-releasing peptide infusions in healthy postmenopausal women. J Clin Endocrinol Metab 86:551-560
47. Veldhuis JD, Anderson SM, Patrie JT, Bowers CY 2001 Estradiol supplementation in postmenopausal women doubles rebound-like release of growth hormone (GH) triggered by sequential infusion and withdrawal of somatostatin: evidence that estrogen facilitates endogenous GHRH drive. J Clin Endocrinol Metab 86:5904-5911
48. Veldhuis JD, Johnson ML 1992 Deconvolution analysis of hormone data. Methods Enzymol 210:539-575
49. Veldhuis JD, Moorman J, Johnson ML 1994 Deconvolution analysis of neuroendocrine data: waveform-specific and waveform-independent methods and applications. Methods Neurosci 20:279-325
50. Faria ACS, Veldhuis JD, Thomer MO, Vance ML 1989 Half-time of endogenous growth hormone (GH) disappearance in normal man after stimulation of GH secretion by GH-releasing hormone and suppression with somatostatin. J Clin Endocrinol Metab 68:535-541
51. Veldhuis JD, Iranmanesh A, Lizarralde G, Johnson ML 1989 Amplitude modulation of a burst-like mode of cortisol secretion subserves the circadian glucocorticoid rhythm in man. Am J Physiol 257:E6-E14
52. Pincus SM 2000 Irregularity and asynchrony in biologic network signals. Methods Enzymol 321:149-182
53. Hartman ML, Pincus SM, Johnson ML, Matthews DH, Faunt LM, Vance ML, Thomer MO, Veldhuis JD 1994 Enhanced basal and disorderly growth hormone secretion distinguish acromegalic from normal pulsatile growth hormone release. J Clin Invest 94:1277-1288
54. Pincus SM, Gevers E, Robinson ICAF, van den Berg G, Roelfsema F, Hartman ML, Veldhuis JD 1996 Females secrete growth hormone with more process irregularity than males in both human and rat. Am J Physiol 270: E107-E115
55. Pincus SM, Hartman ML, Roelfsema F, Thorner MO, Veldhuis JD 1999 Hormone pulsatility discrimination via coarse and short time sampling. Am J Physiol 277:E948-E957
56. Veldhuis JD, Metzger DL, Martha Jr. PM, Mauras N, Kerrigan JR, Keenan B, Rogol AD, Pincus SM 1997 Estrogen and testosterone, but not a non-aromatizable androgen, direct network integration of the hypothalamo-somatotrope (growth hormone)-insulin-like growth factor I axis in the human: evidence from pubertal pathophysiology and sex-steroid hormone replacement. J Clin Endocrinol Metab 82:3414-3420
57. Veldhuis JD, Johnson ML, Veldhuis OL, Straume M, Pincus S 2001 Impact of pulsatility on the ensemble orderliness (approximate entropy) of neurohormone secretion. Am J Physiol 281: R1975-R1985
58. Veldhuis JD, Straume M, Iranmanesh A, Mulligan T, Jaffe CA, Barkan A, Johnson ML, Pincus SM 2001 Secretory process regularity monitors neuroendocrine feedback and feedforward signaling strength in humans. Am J Physiol 280:R721-R729
59. O'Brien R, Power of analysis for linear models. SAS Institute. Proc of the SAS Users Group International Conference, Cary, NC, 1987, p 915-922
60. Winer BJ 1971 Statistical principles in experimental design. New York: McGraw Hill; 232-250
61. O'Brien P 2002 Comparing two samples: extensions of the t, rank-sum, and log-rank tests. J Am Stat Assoc 83:51-61
62. Chapman IM, Bach MA, Cauter EV, Farmer M, Krupa D, Taylor AM, Schilling LM, Cole KY, Skiles EH, Pezzoli SS, Hartman ML, Veldhuis JD, Gormley GJ, Thorner MO 1996 Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretagogue (MK-0677) in healthy elderly subjects. J Clin Endocrinol Metab 81:4249-4257
63. Murphy MG, Bach MA, Plotkin D, Bolognese J, Ng J, Krupa D, Cerchio K, Gertz BJ 1999 Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. The MK-677 Study Group. J Bone Miner Res 14:1182-1188
64. Svensson J, Lonn L, Jansson J-O, Murphy G, Wyss D, Krupa D, Cerchio K, Polvino W, Gertz B, Boseaus I, Sjostrom L, Bengtsson BA 1998 Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. J Clin Endocrinol Metab 83:362-369
65. Locatelli V, Grilli R, Torsello A, Cella SG, Wehrenberg WB, Mueller EE 1994 Growth hormone-releasing hexapeptide is a potent stimulator of growth hormone gene expression and release in the growth hormone-releasing hormone-deprived infant rat. Pediatr Res 36:169-174
66. Veldhuis JD, Roemmich JN, Rogol AD 2000 Gender and sexual maturation-dependent contrasts in the neuroregulation of growth hormone secretion in prepubertal and late adolescent males and females: a general clinical research center-based study. J Clin Endocrinol Metab 85:2385-2394
67. Martha Jr PM, Goorman KM, Blizzard RM, Rogol AD, Veldhuis JD 1992 Endogenous growth hormone secretion and clearance rates in normal boys as determined by deconvolution analysis: relationship to age, pubertal status and body mass. J Clin Endocrinol Metab 74:336-344
68. Martha Jr PM, Rogol AD, Veldhuis JD, Blizzard RM 1996 A longitudinal assessment of hormonal and physical alterations during normal puberty in boys. H. The neuroendocrine growth hormone axis during late prepuberty. J Clin Endocrinol Metab 81:4068-4074
69. Bowers CY, Granda-Ayala R 1996 GHRP-2, GHRH and SRIF interrelationships during chronic administration of GHRP-2 to humans. J Pediatr Endocrinol Metab 9(Suppl 3):261-270
70. Bowers CY, Granda-Ayala R 2001 Growth hormone/insulin-like growth factor-1 response to acute and chronic growth hormone-releasing peptide-2, growth hormone-releasing hormone 1-44NH2 and in combination in older men and women with decreased growth hormone secretion. Endocrine 14: 79-86
71. Bowers CY, Granda-Ayala R, Parulkar A, Anand M, Baker V, Reynolds GA, Veldhuis JD. Impact of GHRP-2 infusion for 30-90 days in older men and women with decreased GH secretion. Proc at the 81st Annual Meeting of The Endocrine Society, San Diego, CA, 1999, p 571
72. Bowers CY, Momany F, Reynolds GA, Chang D, Hong A, Chang K 1980 Structure-activity relationships of a synthetic pentapeptide that specifically releases growth hormone in vitro. Endocrinology 106:663-667
73. Fairhall KM, Mynett A, Robinson IC 1995 Central effects of growth hormone-releasing hexapeptide (GHRP-6) on growth hormone release are inhibited by central somatostatin action. J Endocrinol 144:555-560
74. Hurley DL, Reynolds GA, Veldhuis JD, Bowers CY, Long-term GH releasing peptide-1 treatment increases pituitary GH mRNA. Proc of the 85th Annual Meeting of The Endocrine Society, Philadelphia, PA, 2003, p 377
75. Codner E, Cassorla F, Tiulpakov AN, Melicq MV, Avila A, Pescovitz OH, Svensson J, Cerchio K, Krupa D, Gertz BJ, Murphy G 2001 Effects of oral administration of ibutamoren mesylate, a nonpeptide growth hormone secretagogue, on the growth hormone-insulin-like growth factor I axis in growth hormone-deficient children. Clin Pharmacol Ther 70:91-98
76. Klinger B, Silbergeld A, Deghenghi R, Frenkel J, Laron Z 1996 Desensitization from long-term intranasal treatment with hexarelin does not interfere with the biological effects of this growth hormone-releasing peptide in short children. Eur J Endocrinol 134:716-719
77. Laron Z, Frenkel J, Deghenghi R, Anin S, Klinger B, Silbergeld A 1995 Intranasal administration of the GHRP hexarelin accelerates growth in short children. Clin Endocrinol (Oxf) 43:631-635
78. Mericq V, Cassorla F, Salazar T, Avila A, Iniguez G, Bowers CY, Merriam GR 1998 Effects of eight months treatment with graded doses of a growth hormone (GH)-releasing peptide in GH-deficient children. J Clin Endocrinol Metab 83:2355-2360
79. Pihoker C, Badger TM, Reynolds GA, Bowers CY 1997 Treatment effects of intranasal growth hormone releasing peptide-2 in children with short stature. J Endocrinol 155:79-86
80. Rajaram S, Baylink DJ, Mohan S 1997 Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. Endocr Rev 18:801-831
81. Farhy LS, Straume M, Johnson ML, Kovatchev BP, Veldhuis JD 2001 A construct of interactive feedback control of the GH axis in the male. Am J Physiol 281:R38-R51
82. Farhy LS, Straume M, Johnson ML, Kovatchev B, Veldhuis JD 2002 Unequal autonegative feedback by GH models the sexual dimorphism in GH secretory dynamics. Am J Physiol 282:R753-R764
83. Ho KKY, Evans WS, Blizzard RM, Veldhuis JD, Merriam GR, Samojlik E, Furlanetto R, Rogol AD, Kaiser DL, Thorner MO 1987 Effects of sex and age on the 24-hour profile of growth hormone secretion in man: importance of endogenous estradiol concentrations. J Clin Endocrinol Metab 64:51-58
84. Winer LM, Shaw MA, Baumann G 1990 Basal plasma growth hormone levels in man: new evidence for rhythmicity of growth hormone secretion. J Clin Endocrinol Metab 70:1678-1686
85. van den Berg G, Veldhuis JD, Frolich M, Roelfsema F 1996 An amplitude-specific divergence in the pulsatile mode of GH secretion underlies the gender difference in mean GH concentrations in men and premenopausal women. J Clin Endocrinol Metab 81:2460-2466
86. Loche S, Colao A, Cappa M, Bellone J, Aimaretti G, Farello G, Faedda A, Lombardi G, Deghenghi R, Ghigo E 1997 The growth hormone response to hexarelin in children: reproducibility and effect of sex steroids. J Clin Endocrinol Metab 82:861-864
87. Petersenn S, Rasch AC, Penshom M, Beil FU, Schulte HM 2001 Genomic structure and transcriptional regulation of the human growth hormone secretagogue receptor. Endocrinology 142:2649-2659
88. Ho KKY, Hoffman DM 1993 Aging and growth hormone. Horm Res 41:80-86
89. Veldhuis JD, Iranmanesh A, Weltman A 1997 Elements in the pathophysiology of diminished growth hormone (GH) secretion in aging humans. Endocrine 7:41-48
90. Arvat E, Ceda GP, Di Vito L, Ramunni J, Gianotti L, Ghigo E 1998 Age-related variations in the neuroendocrine control, more than impaired receptor sensitivity, cause the reduction in the GH-releasing activity of GHRP's in human aging. Pituitary 1:51-58
91. Baxter RC 2000 Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and intrinsic bioactivities. Am J Physiol 278:E967-E976
92. Maccario M, Veldhuis JD, Broglio F, Di Vito L, Arvat E, Deghenghi R, Ghigo E 2002 Impact of two or three daily subcutaneous injections of hexarelin, a synthetic GH secretagogue (GHS), on 24-hour GH, prolactin, ACTH and cortisol secretion in the human. Eur J Endocrinol 146:311-318
93. Rahim A, O'Neill PA, Shalet SM 1999 The effect of chronic hexarelin administration on the pituitary-adrenal axis and prolactin. Clin Endocrinol (Oxf) 50:77-84
94. Broglio F, Arvat E, Benso A, Gorrero C, Muccioli G, Papotti M, van der Lely AJ, Deghenghi R, Ghigo E 2001 Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humans. J Clin Endocrinol Metab 86:5083-5086
95. Ghigo E, Arvat E, Ramunni J, Colao A, Gianotti R, Deghenghi G, Lombardi G, Camanni F 1997 Adrenocorticotropin- and cortisol-releasing effect of hexarelin, a synthetic growth hormone-releasing peptide, in normal subjects and patients with Cushing's syndrome. J Clin Endocrinol Metab 82:2439-2444
96. Isozaki O, Tsushima T, Miyakawa M, Demura H, Seld H 1999 Interaction between leptin and growth hormone (GM/IGF-I axis. Endocr J 46:S17-S24
97. Van den Berghe G, Wouters P, Weekers F, Mohan S, Baxter RX, Veldhuis JD, Bowers CY, Bouillon R 1999 Reactivation of pituitary hormone release and metabolic improvement by infusion of growth hormone-releasing peptide and thyrotropin-releasing hormone in patients with protracted critical illness. J Clin Endocrinol Metab 84:1311-1323
98. Van den Berghe G, Baxter RC, Weekers F, Wouters P, Bowers CY, Iranmanesh A, Veldhuis JD, Boillon R 2002 The combined administration of GH-releasing peptide-2 (GHRP-2), TRH and GnRH to men with prolonged critical illness evokes superior endocrine and metabolic effects compared to treatment with GHRP-2 alone. Clin Endocrinol (Oxf) 56:655-669
99. Van den Berghe G, Baxter RC, Weekers F, Wouters P, Bowers CY, Veldhuis JD 2000 A paradoxical gender dissociation within the growth hormone/ insulin-like growth factor I axis during protracted critical illness. J Clin Endocrinol Metab 85:183-192